CN Patent

CN112225734B — Kras g12c抑制剂及其用途

Assigned to Nanjing Ruijie Pharma Co ltd · Expires 2021-12-07 · 4y expired

What this patent protects

本发明涉及KRAS G12C抑制剂及其用途，具体地，本发明提供一种式(I)所示化合物，或其立体异构体，或其阻转异构体，或其药学上可接受的盐，或其互变异构体，或其前药。

USPTO Abstract

本发明涉及KRAS G12C抑制剂及其用途，具体地，本发明提供一种式(I)所示化合物，或其立体异构体，或其阻转异构体，或其药学上可接受的盐，或其互变异构体，或其前药。

Drugs covered by this patent

Patent Metadata

Patent number
CN112225734B
Jurisdiction
CN
Classification
—
Expires
2021-12-07
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Ruijie Pharma Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.